Glaukos Corp (GKOS)

$100.20 +3.40 (3.51%)
Market Cap 5.72B
Revenue (ttm) 383.48M
Net Income (ttm) -146.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.17%
Debt to Equity Ratio 0.00
Volume 549,783
Avg Vol 977,426
Day's Range N/A - N/A
Shares Out 57.14M
Stochastic %K 29%
Beta 0.80
Analysts Strong Sell
Price Target $128.54

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 367 9600
Fax: 949 367 9984
Address:
One Glaukos Way, Aliso Viejo, United States
Estimize
Estimize Jun. 19 at 12:03 PM
Wall St is expecting -0.26 EPS for $GKOS Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/gkos?chart=historical&metric_name=eps&utm_c
0 · Reply
JarvisFlow
JarvisFlow Jun. 18 at 10:00 AM
Mizuho updates rating for Glaukos ( $GKOS ) to Neutral, target set at 115 → 140.
0 · Reply
JarvisFlow
JarvisFlow Jun. 6 at 10:30 AM
Needham has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 137 → 149.
0 · Reply
ZacksResearch
ZacksResearch May. 21 at 11:21 AM
$GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. Discover more: https://www.zacks.com/stock/news/2475121/heres-why-you-should-retain-glaukos-stock-in-your-portfolio?cid=sm-stocktwits-2-2475121-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2475121_TEASER
0 · Reply
Kingofstocks0001
Kingofstocks0001 May. 7 at 7:45 PM
$GKOS This will double soon
1 · Reply
JarvisFlow
JarvisFlow May. 6 at 2:38 PM
Morgan Stanley updates rating for Glaukos ( $GKOS ) to Underweight, target set at 110 → 72.
1 · Reply
Kingofstocks0001
Kingofstocks0001 May. 2 at 5:37 PM
$GKOS iDose is a game changer. This stock is undervalued. Wouldn’t be surpised as it rises to $200.
0 · Reply
mikesterz7
mikesterz7 May. 2 at 1:01 AM
$GKOS Wells Fargo downgraded Glaukos to Equal Weight from Overweight with a price target of $86, down from $160. The growth runway for iDose is priced into the shares while the base business offers no upside, the firm tells investors in a research note.
0 · Reply
JarvisFlow
JarvisFlow May. 1 at 3:44 PM
Truist Securities updates rating for Glaukos ( $GKOS ) to Buy, target set at 140 → 135.
0 · Reply
JarvisFlow
JarvisFlow May. 1 at 1:00 PM
Wells Fargo updates rating for Glaukos ( $GKOS ) to Equal-Weight, target set at 160 → 86.
0 · Reply
Latest News on GKOS
Glaukos Announces Participation in Upcoming Investor Conferences

May 13, 2025, 7:00 AM EDT - 6 weeks ago

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 10:05 PM EDT - 7 weeks ago

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Glaukos Announces First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 7 weeks ago

Glaukos Announces First Quarter 2025 Financial Results

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr 29, 2025, 11:30 AM EDT - 2 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX DHR INSM ISRG LLY RDNT

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 23, 2025, 7:00 AM EDT - 2 months ago

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Announces the Release of its 2024 Sustainability Report

Apr 16, 2025, 7:00 AM EDT - 2 months ago

Glaukos Announces the Release of its 2024 Sustainability Report

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Apr 9, 2025, 7:00 AM EDT - 2 months ago

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Mar 11, 2025, 7:00 AM EDT - 3 months ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Feb 24, 2025, 9:12 AM EST - 4 months ago

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 24, 2025, 7:00 AM EST - 4 months ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Feb 21, 2025, 10:27 AM EST - 4 months ago

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 21, 2025, 4:29 AM EST - 4 months ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 4:05 PM EST - 4 months ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Jan 23, 2025, 7:00 AM EST - 5 months ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Jan 14, 2025, 4:05 PM EST - 5 months ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Dec 31, 2024, 8:59 AM EST - 6 months ago

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 23, 2024, 7:00 AM EST - 6 months ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 21, 2024, 7:04 AM EST - 6 months ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Dec 17, 2024, 7:00 AM EST - 6 months ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Dec 2, 2024, 2:29 PM EST - 7 months ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

ISRG NVRO SYK

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Nov 5, 2024, 12:21 PM EST - 8 months ago

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:03 PM EST - 8 months ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Glaukos Announces Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 8 months ago

Glaukos Announces Third Quarter 2024 Financial Results

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Oct 16, 2024, 4:05 PM EDT - 8 months ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Oct 14, 2024, 7:00 AM EDT - 9 months ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Oct 9, 2024, 7:00 AM EDT - 9 months ago

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Sep 23, 2024, 1:30 AM EDT - 9 months ago

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 8:57 PM EDT - 11 months ago

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Glaukos Announces Second Quarter 2024 Financial Results

Jul 31, 2024, 4:05 PM EDT - 11 months ago

Glaukos Announces Second Quarter 2024 Financial Results

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Jul 10, 2024, 9:05 AM EDT - 1 year ago

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

V HELE LZ SPOT

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Jul 10, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

May 1, 2024, 8:42 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

Glaukos Announces First Quarter 2024 Financial Results

May 1, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces First Quarter 2024 Financial Results

Glaukos Announces the Release of its 2023 Sustainability Report

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces the Release of its 2023 Sustainability Report

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 11:13 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Jan 31, 2024, 7:00 AM EST - 1 year ago

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Jan 9, 2024, 7:00 AM EST - 1 year ago

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Alger's Amy Zhang gives her top small-cap stock picks for 2024

Jan 5, 2024, 7:31 AM EST - 1 year ago

Alger's Amy Zhang gives her top small-cap stock picks for 2024

NTRA

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Dec 14, 2023, 7:00 AM EST - 1 year ago

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Glaukos Announces Participation in Stifel Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 1 year ago

Glaukos Announces Participation in Stifel Healthcare Conference

Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript

Nov 1, 2023, 11:04 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript

Glaukos Announces Third Quarter 2023 Financial Results

Nov 1, 2023, 4:05 PM EDT - 1 year ago

Glaukos Announces Third Quarter 2023 Financial Results

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting

Oct 31, 2023, 7:00 AM EDT - 1 year ago

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting

Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023

Oct 11, 2023, 7:00 AM EDT - 1 year ago

Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Aug 23, 2023, 7:00 AM EDT - 1 year ago

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Estimize
Estimize Jun. 19 at 12:03 PM
Wall St is expecting -0.26 EPS for $GKOS Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/gkos?chart=historical&metric_name=eps&utm_c
0 · Reply
JarvisFlow
JarvisFlow Jun. 18 at 10:00 AM
Mizuho updates rating for Glaukos ( $GKOS ) to Neutral, target set at 115 → 140.
0 · Reply
JarvisFlow
JarvisFlow Jun. 6 at 10:30 AM
Needham has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 137 → 149.
0 · Reply
ZacksResearch
ZacksResearch May. 21 at 11:21 AM
$GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. Discover more: https://www.zacks.com/stock/news/2475121/heres-why-you-should-retain-glaukos-stock-in-your-portfolio?cid=sm-stocktwits-2-2475121-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2475121_TEASER
0 · Reply
Kingofstocks0001
Kingofstocks0001 May. 7 at 7:45 PM
$GKOS This will double soon
1 · Reply
JarvisFlow
JarvisFlow May. 6 at 2:38 PM
Morgan Stanley updates rating for Glaukos ( $GKOS ) to Underweight, target set at 110 → 72.
1 · Reply
Kingofstocks0001
Kingofstocks0001 May. 2 at 5:37 PM
$GKOS iDose is a game changer. This stock is undervalued. Wouldn’t be surpised as it rises to $200.
0 · Reply
mikesterz7
mikesterz7 May. 2 at 1:01 AM
$GKOS Wells Fargo downgraded Glaukos to Equal Weight from Overweight with a price target of $86, down from $160. The growth runway for iDose is priced into the shares while the base business offers no upside, the firm tells investors in a research note.
0 · Reply
JarvisFlow
JarvisFlow May. 1 at 3:44 PM
Truist Securities updates rating for Glaukos ( $GKOS ) to Buy, target set at 140 → 135.
0 · Reply
JarvisFlow
JarvisFlow May. 1 at 1:00 PM
Wells Fargo updates rating for Glaukos ( $GKOS ) to Equal-Weight, target set at 160 → 86.
0 · Reply
GetVector
GetVector May. 1 at 12:55 PM
Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $CFLT, $GKOS, $TTMI.
0 · Reply
briefingcom
briefingcom May. 1 at 12:07 PM
Gapping down: $ARVN -31.3% $OGN -15.4% $CFLT -10.9% $GKOS -9.9% $AGI -9.2%
0 · Reply
anachartanalyst
anachartanalyst May. 1 at 12:01 PM
$GKOS https://anachart.com/wp-content/uploads/ana_temp/1746100905_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow May. 1 at 12:00 PM
Needham has updated their rating for Glaukos ( $GKOS ) to Buy with a price target of 115.
0 · Reply
Parnell8
Parnell8 May. 1 at 10:06 AM
$GKOS missed idose watch out below.. could see $70S
1 · Reply
TickrTalk0007
TickrTalk0007 Apr. 28 at 7:19 PM
$GKOS won't outperform until they have a legit pharma presence in retina. glaucoma will only take you so far. they need to re-assess their pipeline and pick high value target markets...retina is not too far from where they are. anterior segment is a dog. just look at the physician survey from Sightline conference.
1 · Reply
JarvisFlow
JarvisFlow Apr. 16 at 5:12 PM
Mizuho has updated their rating for Glaukos ( $GKOS ) to Outperform with a price target of 175.
0 · Reply
JarvisFlow
JarvisFlow Apr. 15 at 2:36 PM
Piper Sandler has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Overweight with a target price of 180 → 165.
0 · Reply
JarvisFlow
JarvisFlow Apr. 11 at 1:28 PM
Truist Securities has updated their rating for Glaukos ( $GKOS ) to Buy with a price target of 140.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 29 at 2:53 PM
$GKOS Digging the iDose TR launch. Looks like Glaukos is positioning itself nicely in ophthalmology. Their pipeline seems robust. Might add some shares on next dip. Watching closely for Q1 performance and international growth trajectory. compelling article: https://beyondspx.com/article/glaukos-corporation-nyse-gkos-a-disruptive-ophthalmic-pioneer-transforming-vision-care
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Mar. 26 at 11:44 PM
The attached table notes the YTD change in share price for all 44 commercial-stage non-oncology focused bios (with first or major approvals since 1/1/2017) with market caps north of $750MM (excl. ARGX). ITCI was the only bio in this peer group to be acquired this quarter. Our records indicate $XERS $AXSM & $VRNA have shown the largest gains so far QTD while $GKOS & SRPT are the biggest lowers. This is not investment advice but investors we respect believe $SRPT offers the best risk v reward in this peer group (but exercise caution as SRPT’s new therapy may have led to a SAE…death). You’ll also note how many of the 44 in this peer group saw share price increases by month. Marcj 2025 was dismal with only 16 of the 44 trading higher. Commercial-stage oncology focused bio fared much worse by this metric in March.
0 · Reply
Kingofstocks0001
Kingofstocks0001 Mar. 20 at 3:33 AM
$GKOS to the moon
0 · Reply